ChartRow logo
Data provided bySource: Twelve Data
ARWR
$42.99-2.76%
as of close, Nov 17, 2026
☾ AH $42.99 -2.76%
PeersROIVAXSMCYTKIBRXSPYQQQ
Share this page

ARWR — Arrowhead Pharmaceuticals Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in ARWR be worth today? →
ARWR returns: By year · By month · By week · Trailing

Price data

Price
$42.99
YTD price return
-35.25%
YTD total return
-35.25%
Market cap
6.1B
Enterprise value
5.4B
Shares outstanding
141.4M
52W low
$37.06
52W high
$95.49
From 52W high
-54.98%
From 52W low
+16.00%
52W range
10%$37.06–$95.49
Beta
1.27

Volume

Rel volume
1.77×
30D volume
2.1M
30D $ vol
114.4M

Insider trading

Insider net 1W
none
Insider net 1M
none
Insider net 3M
none
Insider net 1Y
−$10.3M

Form 4 transactions by trade date, as filed; latest on file 2026-08-18.

Fundamentals

Sales (ttm)
450.8M
Sales/share
$3.19
EPS (ttm)
-$5.11
FCF (ttm)
-283.9M
FCF/share
-$2.01
Book value/share
$0.36
Net margin
-160.64%
ROE
-1439.40%
ROA
-41.66%
Debt / equity
16.67×
Current ratio
4.14

Growth (CAGR, ttm) · 10Y

Sales
-45.67%+23.25%+26.67%+121.56%
Shares
+4.10%+9.58%+6.23%+6.66%

Per-share growth (CAGR, ttm) · 10Y

Sales/share
-47.81%+12.48%+19.24%+107.72%
Book value/share
-89.64%-47.95%-38.09%-12.07%
Price
+7.08%+15.28%-7.58%+25.48%
Total return
+7.08%+15.28%-7.58%+25.48%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-8.4×
Fwd P/E
-14.7×
P/S (ttm)
13.5×
P/B (mrq)
120.8×
EV/Sales (ttm)
12.0×
FCF yield (ttm)
-4.67%
Buyback yield (realized, 1y)
-4.10%
Shareholder yield (realized, 1y)
-4.10%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/S
26th
P/B
99th

Bar = where today’s multiple sits in ARWR’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
-2.76%
5D
-12.27%
1M
-23.09%
3M
-51.53%
YTD
-35.25%
1Y
+7.07%
5Y
-32.55%
1D
-2.76%
5D
-12.27%
1M
-23.09%
3M
-51.53%
YTD
-35.25%
1Y
+7.07%
5Y
-32.55%

Fundamentals#

Revenue

5Y CAGR +26.7%10Y CAGR +121.5%YoY −85.3%
$450.8M FY26$37.8M Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Operating income

5Y n/m10Y n/mYoY n/m
−$707.2M FY26−$436.6M Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$5.11 FY26−$3.00 Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Free cash flow

5Y n/m10Y n/mYoY n/m
−$283.9M FY26−$195.8M Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

FY26: operating cash flow −$271.9M, capex −$12M

Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Q4 2026: operating cash flow −$192.4M, capex −$3.4M

Shares (diluted)

5Y +36.5%5Y +36.5%YoY +5.6%
141.6M FY26142.5M Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Net income

5Y n/m10Y n/mYoY n/m
−$724.2M FY26−$428M Q4 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Full ARWR financials →

About Arrowhead Pharmaceuticals#

Data provided bySource: Twelve Data

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for intractable diseases using RNA interference, a gene-silencing approach designed to reduce the production of disease-causing proteins. Arrowhead Pharmaceuticals focuses on therapeutic areas including cardiometabolic, liver, pulmonary, neuromuscular, complement-mediated, and central nervous system disorders. Its portfolio includes both commercial and clinical-stage programs built around its targeted RNAi platform, which is designed for tissue-specific delivery and precise gene suppression. The company works across product development, clinical research, and commercialization, with a pipeline that includes multiple investigational therapies aimed at genetically driven diseases. Arrowhead Pharmaceuticals serves the broader healthcare market by advancing treatments for complex conditions with limited options, positioning itself as a specialized player in RNA-based drug development.

Pasadena, CA·711 employees·Biotechnology·arrowheadpharma.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding ARWR#

24 of the 193 ETFs ChartRow carries live hold ARWR. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
XBISPDR S&P Biotech ETF1.1%
IBBiShares Biotechnology ETF0.8%
IJHiShares Core S&P Mid-Cap ETF0.3%
MDYSPDR S&P MidCap 400 ETF Trust0.3%
VBKVanguard Small-Cap Growth ETF0.3%
IWPiShares Russell Mid-Cap Growth ETF0.2%
VHTVanguard Health Care ETF0.1%
VXFVanguard Extended Market ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%